EMA

Yesintek, a ustekinumab biosimilar, indicated for the plaque psoriasis treatment has received approval from both the EMA and FDA.

Biocon’s Yesintek receives EMA and FDA approval as the next ustekinumab biosimilar

Lecanemab to treat Alzheimer's disease

Lecanemab approved by EMA in early Alzheimer’s after re-evaluation

Gastric cancer treatment

Zolbetuximab demonstrates significant benefit in gastric cancer and receives approval in the EU

Lecanemab slows Alzheimer's disease progression.

Lecanemab, a breakthrough Alzheimer’s drug, rejected by EMA

EMA considers dropping efficacy studies for certain biosimilars